| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-90020-25ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-65543SS | |||
| Azide and BSA Free | NBP2-80661 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-71663SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-77913-25ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-48337SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| IHC-Prediluted | NBP2-44808 | |||
| Azide and BSA Free | NBP2-34689-0.1mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-48338SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-27216 | |||
| Azide and BSA Free | NBP2-25199SS | |||
| Azide and BSA Free | NBP2-27216-25ug | |||
![Immunohistochemistry-Paraffin: MMR/CD206/Mannose Receptor Antibody [NBP1-90020] - Staining of human cerebral cortex, liver, lung and placenta using Anti-MMR/CD206/Mannose Receptor antibody NBP1-90020 (A) shows similar protein distribution across tissues to independent antibody NBP2-33439 (B).](http://images.novusbio.com/fullsize/MMR-CD206-Mannose-Receptor-Antibody-Immunohistochemistry-Paraffin-NBP1-90020-img0026.jpg "<b>Independent Antibodies Validation. </b>Immunohistochemistry-Paraffin: MMR/CD206/Mannose Receptor Antibody [NBP1-90020] - Staining of human cerebral cortex, liver, lung and placenta using Anti-MMR/CD206/Mannose Receptor antibody NBP1-90020 (A) shows similar protein distribution across tissues to independent antibody NBP2-33439 (B).")
![Immunohistochemistry-Paraffin: MMR/CD206/Mannose Receptor Antibody [NBP1-90020] - Staining of human lung shows moderate to strong cytoplasmic positivity in macrophages.](http://images.novusbio.com/fullsize/MMR-CD206-Mannose-Receptor-Antibody-Immunohistochemistry-Paraffin-NBP1-90020-img0021.jpg)
![Immunohistochemistry-Paraffin: MMR/CD206/Mannose Receptor Antibody [NBP1-90020] - Staining of human cerebral cortex shows no cytoplasmic positivity in neuronal cells.](http://images.novusbio.com/fullsize/MMR-CD206-Mannose-Receptor-Antibody-Immunohistochemistry-Paraffin-NBP1-90020-img0019.jpg)
![Immunohistochemistry-Paraffin: MMR/CD206/Mannose Receptor Antibody [NBP1-90020] - Staining of human liver shows moderate cytoplasmic positivity in Kupffer cells.](http://images.novusbio.com/fullsize/MMR-CD206-Mannose-Receptor-Antibody-Immunohistochemistry-Paraffin-NBP1-90020-img0020.jpg)
![Immunohistochemistry-Paraffin: MMR/CD206/Mannose Receptor Antibody [NBP1-90020] - Staining of human placenta shows moderate to strong cytoplasmic positivity in Hofbauer cells.](http://images.novusbio.com/fullsize/MMR-CD206-Mannose-Receptor-Antibody-Immunohistochemistry-Paraffin-NBP1-90020-img0022.jpg)
![Flow Cytometry: CD90/Thy1 Antibody (OX-7) [NB100-65543] - Staining of rat thymus.](http://images.novusbio.com/fullsize/CD90-Thy1-Antibody-OX-7-Flow-Cytometry-NB100-65543-img0006.jpg "Flow Cytometry: CD90/Thy1 Antibody (OX-7) [NB100-65543] - Staining of rat thymus.")
![Flow Cytometry: CD90/Thy1 Antibody (OX-7) [NB100-65543] - Staining of rat thymus with MOUSE ANTI RAT CD90 (THY 1.1).](http://images.novusbio.com/fullsize/CD90-Thy1-Antibody-OX-7-Flow-Cytometry-NB100-65543-img0001.jpg)
![Flow Cytometry: CD90/Thy1 Antibody (OX-7) [NB100-65543] - Staining of rat thymocytes.](http://images.novusbio.com/fullsize/CD90-Thy1-Antibody-OX-7-Flow-Cytometry-NB100-65543-img0002.jpg)
![Flow Cytometry: CD90/Thy1 Antibody (OX-7) [NB100-65543] - Staining of rat thymocytes.](http://images.novusbio.com/fullsize/CD90-Thy1-Antibody-OX-7-Flow-Cytometry-NB100-65543-img0003.jpg)
![Flow Cytometry: CD90/Thy1 Antibody (OX-7) [NB100-65543] - Staining of rat thymus cell.](http://images.novusbio.com/fullsize/CD90-Thy1-Antibody-OX-7-Flow-Cytometry-NB100-65543-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: CD31/PECAM-1 Antibody [NBP1-71663] - Staining of mouse glioma tissue using CD31/PECAM-1 Antibody (NBP1-71663) at a dilution of 1:2500. Image provided by Dr. Eric Woolf of Dignity Health.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-71663-img0009.jpg "Immunocytochemistry/Immunofluorescence: CD31/PECAM-1 Antibody [NBP1-71663] - Staining of mouse glioma tissue using CD31/PECAM-1 Antibody (NBP1-71663) at a dilution of 1:2500. Image provided by Dr. Eric Woolf of Dignity Health.")
![Simple Western: CD31/PECAM-1 Antibody [NBP1-71663] - Image shows a specific band for CD31/PECAM 1 in 0.5 mg/mL of HUVEC lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-Simple-Western-NBP1-71663-img0010.jpg)
![<b>Biological Strategies Validation. </b>Immunohistochemistry: CD31/PECAM-1 Antibody [NBP1-71663] - 5-HTR1A agonist enhances neovascularization during skin wound healing (excisional punch biopsy model). CD31/PECAM-1 endothelial cell immunohistochemical staining at day 5 (A,B) and day 7 (E,F), image scale bars represented at 50 um. Results were presented as mean +/- SEM (n = 5 images per wound). Two-way ANOVA was performed and significance levels were set at *P < 0.05, **P < 0.01. Image collected and cropped by CiteAb from the following publication (//www.frontiersin.org/article/10.3389/fphar.2018.01406/full), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-Immunohistochemistry-NBP1-71663-img0012.jpg)
![Western Blot: CD31/PECAM-1 Antibody [NBP1-71663] - Snail and EndMT-related protein expression in lungs in orthotopic murine 4T1 breast cancer model. ag Expression of Snail (see Methods). Levels of CD31/PECAM-1 determined by western blot analysis in pooled (n = 6) samples in control and 4T1 breast cancer-bearing mice from the 1st to 5th week after 4T1 cancer cell inoculation (see Methods). Results presented as fold change vs control sample corresponding to healthy mice. Total protein after transfer was used as loading control Image collected and cropped by Citeab from the following publication (Nitric oxide deficiency and endothelial-mesenchymal transition of pulmonary endothelium in the progression of 4T1 metastatic breast cancer in mice. Breast Cancer Res (2018) licensed under a CC-BY license](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-Western-Blot-NBP1-71663-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: CD31/PECAM-1 Antibody [NBP1-71663] - HUVEC cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with CD31/PECAM-1 Antibody at 5 ug/mL overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse Dylight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-71663-img0011.jpg)
![Flow Cytometry: CD31/PECAM-1 Antibody [NBP1-71663] - CD31/PECAM-1 Antibody was tested in WeHi cells with Dylight 488 (green) alongside a matched isotype control (black).](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-Flow-Cytometry-NBP1-71663-img0005.jpg)
![Western Blot: CD31/PECAM-1 Antibody [NBP1-71663] - Detection of CD31 in HUVEC cell lysates.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-Western-Blot-NBP1-71663-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: CD63 Antibody (MEM-259) [NB100-77913] - Human HeLa cells. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Immunocytochemistry-Immunofluorescence-NB100-77913-img0015.jpg "Immunocytochemistry/Immunofluorescence: CD63 Antibody (MEM-259) [NB100-77913] - Human HeLa cells. ICC/IF image submitted by a verified customer review.")
![Western Blot: CD63 Antibody (MEM-259) [NB100-77913] - Immunoblot analysis of CD63, CD81, TSG101, and CD9 protein in LSC-Exo and MSC-Exo. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41467-020-14344-7), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Western-Blot-NB100-77913-img0016.jpg)
![Immunohistochemistry-Paraffin: CD63 Antibody (MEM-259) [NB100-77913] - Staining of human spleen (paraffin sections) using anti-CD63 (MEM-259).](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Immunohistochemistry-Paraffin-NB100-77913-img0018.jpg)
![Flow Cytometry: CD63 Antibody (MEM-259) [NB100-77913] - Flow Cytometry: CD63 Antibody (MEM-259) [FITC] [NB500-483] - Analysis of IgE-activated peripheral blood stained with anti-human CD63 (MEM-259) PE-CyTM5. Image using the FITC form of this antibody.](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Flow-Cytometry-NB100-77913-img0014.jpg)
![Immunocytochemistry/Immunofluorescence: CD63 Antibody (MEM-259) [NB100-77913] - Staining of human skin fibroblasts with anti-CD63 (MEM-259; green) after co-incubation of living cells with human Transferrin - Dyomics 547 (red); cell nuclei stained with DAPI (blue).](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Immunocytochemistry-Immunofluorescence-NB100-77913-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: CD63 Antibody (MEM-259) [NB100-77913] - Staining of CD63 in human primary fibroblasts using anti-CD63 (MEM-259; green). Actin cytoskeleton was decorated by phalloidin (red) and cell nuclei stained with DAPI (blue).](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Immunocytochemistry-Immunofluorescence-NB100-77913-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: CD63 Antibody (MEM-259) [NB100-77913] - Staining of CD63 in human HeLa cell line using anti-CD63 (MEM-259; green). Actin cytoskeleton was decorated by phalloidin (red) and cell nuclei stained with DAPI (blue).](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Immunocytochemistry-Immunofluorescence-NB100-77913-img0003.jpg)
![Flow Cytometry: CD63 Antibody (MEM-259) [NB100-77913] - Analysis using the FITC conjugate of NB100-77913. Staining of peripheral blood lymphocytes from a patient with allergy to bee venom after stimulation with bee venom, stained with anti-human CD63 (MEM-259) FITC.](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Flow-Cytometry-NB100-77913-img0006.jpg)
![Flow Cytometry: CD63 Antibody (MEM-259) [NB100-77913] - Analysis of IgE-activated peripheral blood stained with anti-human CD63 (MEM-259) PE.](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Flow-Cytometry-NB100-77913-img0009.jpg)
![Flow Cytometry: CD63 Antibody (MEM-259) [NB100-77913] - Analysis of IgE-activated peripheral blood stained with anti-human CD63 (MEM-259) purified, GAM-APC.](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Flow-Cytometry-NB100-77913-img0010.jpg)
![Flow Cytometry: CD63 Antibody (MEM-259) [NB100-77913] - Analysis of IgE-activated peripheral blood stained with anti-human CD63 (MEM-259) PerCP-CyTM5.5.](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Flow-Cytometry-NB100-77913-img0011.jpg)
![Flow Cytometry: CD63 Antibody (MEM-259) [NB100-77913] - Analysis of IgE-activated peripheral blood stained with anti-human CD63 (MEM-259) PerCP.](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Flow-Cytometry-NB100-77913-img0012.jpg)
![Flow Cytometry: CD63 Antibody (MEM-259) [NB100-77913] - Flow Cytometry: CD63 Antibody (MEM-259) [FITC] [NB500-483] - Analysis of IgE-activated peripheral blood stained with anti-human CD63 (MEM-259) Alexa Fluor® 488. Image using the FITC form of this antibody.](http://images.novusbio.com/fullsize/CD63-Antibody-MEM-259-Flow-Cytometry-NB100-77913-img0013.jpg)
![Western Blot: CD63 Antibody (MEM-259) - BSA Free [NB100-77913] - Cytokine & checkpoint molecule arrays from plasma exosomes showed a decreased concentration of IFN-gamma , IL-10, IL-13, B7-1, B7-2, & ICOSL in GBM patients in comparison to normal donors. (A) Quantification of IFN-gamma , IL-10, & IL-13 in plasma exosomes from normal donors & grade 4 GBM patients' plasma exosomes (mean ± SEM, n = 4/group, *P < 0.05). (B) Quantification of B7-1, B7-2, & ICOSL in plasma exosomes from normal donors & grade 4 GBM patients' plasma exosomes (mean ± SEM, n = 4/group). (C) Quantification of the immunosuppressive checkpoint & T cell costimulatory homolog protein PD-L1 in plasma exosomes from normal donors & grade 4 GBM patients' plasma exosomes (mean ± SEM, n = 4/group). Interestingly, PD-L1 is found at similar levels in both normal donor & glioma patient plasma exosomes & these findings were confirmed by western blot. Western Blot analysis also shows that exosomal markers Flotillin-1 & CD63 are found universally in plasma exosomes from normal donors (n = 3), glioblastoma (grade 4) patients (n = 4), & grade 3 glioma patients (n = 3), though CD63 expression may be slightly reduced in glioma patients. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31380286), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-77913_mouse-monoclonal-cd63-antibody-mem-259-310202415532072.jpg)
![Western Blot: nNOS Antibody [NBP1-39681] - Effects of ER alpha and ER beta Antagonists on NE Regulation of VMN nNOS Protein Expression. Micropunch-dissected VMN tissue was obtained from groups of ovariectomized, estradiol-replaced female rats pretreated by intra-VMN delivery of MPP, PHTPP, or vehicle (Veh) prior to NE administration for Western blot analysis of neuronal nitric oxide synthase (nNOS) - Panel 2A,F(5, 12)=12.67,p<.0001 - protein expression. Data depict mean normalized protein optical density (O.D.) values+/-SEMfor groups of rats (n=6 per group) infused with Veh (white bars) or NE (gray bars) after delivery of Veh (solid bars), MPP (diagonal-striped bars), or PHTPP (cross-hatched bars) administration. *p<.05; **p<.01; ***p<.001. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32233668/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/nNOS-Antibody-Western-Blot-NBP1-39681-img0007.jpg "Western Blot: nNOS Antibody [NBP1-39681] - Effects of ER alpha and ER beta Antagonists on NE Regulation of VMN nNOS Protein Expression. Micropunch-dissected VMN tissue was obtained from groups of ovariectomized, estradiol-replaced female rats pretreated by intra-VMN delivery of MPP, PHTPP, or vehicle (Veh) prior to NE administration for Western blot analysis of neuronal nitric oxide synthase (nNOS) - Panel 2A,F(5, 12)=12.67,p<.0001 - protein expression. Data depict mean normalized protein optical density (O.D.) values+/-SEMfor groups of rats (n=6 per group) infused with Veh (white bars) or NE (gray bars) after delivery of Veh (solid bars), MPP (diagonal-striped bars), or PHTPP (cross-hatched bars) administration. *p<.05; **p<.01; ***p<.001. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32233668/) licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: nNOS Antibody [NBP1-39681] - Analysis of anti-nNOS / NOS1 antibody with human brain, cerebellum at concentration 5 ug/ml.](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunohistochemistry-Paraffin-NBP1-39681-img0004.jpg)
![Western Blot: nNOS Antibody [NBP1-39681]](http://images.novusbio.com/fullsize/nNOS-Antibody-Western-Blot-NBP1-39681-img0006.jpg)
![Immunohistochemistry-Paraffin: nNOS Antibody [NBP1-39681] - Analysis of anti-nNOS / NOS1 antibody with human brain, cortex at concentration 5 ug/ml.](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunohistochemistry-Paraffin-NBP1-39681-img0003.jpg)
![Western Blot: nNOS Antibody [NBP1-39681] - Laser-Catapult Microdissection of Immunolabeled ventromedial hypothalamic nucleus (VMN) GABA or Nitrergic Neurons: Western Blot Confirmation of Accuracy of Immunocytochemical Identification of Neurotransmitter Phenotype. VMN neurons were identified in situ for glutamate decarboxylase65/67 (GAD65/67)- (top row, Panel 1A) or neuronal nitric oxide (nNOS)-immunoreactivity (-ir) (bottom row, Panel 2A); representative GAD65/67- or nNOS-ir-positive neurons are indicated by blue arrows. Areas shown in Panels 1A & 2A were rephotographed after positioning of a continuous laser track (depicted in green) around a single GAD65/67-ir (Panel 1B, blue arrow) or nNOS-ir neuron (Panel 2B, blue arrow) & subsequent ejection of the encircled cell by laser pulse (Panels 1C & 2C). Note that this microdissection technique causes negligible destruction of surrounding tissue & minimal inclusion of adjacent tissue. Western blot analysis of triplicate cell lysate pools produced from immunolabeled GAD65/67 (Panel 1D) or nNOS (Panel 2D) neurons from Veh/Veh animals showed that these proteins are expressed in VMN neuron samples obtained by combinatory immunocytochemistry/laser-catapult microdissection. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32233668), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-39681_rabbit-nnos-pab-310202416154636.jpg)
![Western Blot: nNOS Antibody [NBP1-39681] - Effects of ER alpha & ER beta Antagonists on NE Regulation of VMN GAD & nNOS Protein Expression. Micropunch-dissected VMN tissue was obtained from groups of ovariectomized, estradiol-replaced female rats pretreated by intra-VMN delivery of MPP, PHTPP, or vehicle (Veh) prior to NE administration for Western blot analysis of neuronal nitric oxide synthase (nNOS)—Panel 2A, F(5, 12) = 12.67, p < .0001—or glutamate decarboxylase65/67 (GAD)—Panel 2B, F(5, 12) = 7.13, p = .0003—protein expression. Data depict mean normalized protein optical density (O.D.) values ± SEM for groups of rats (n = 6 per group) infused with Veh (white bars) or NE (gray bars) after delivery of Veh (solid bars), MPP (diagonal-striped bars), or PHTPP (cross-hatched bars) administration. *p < .05; **p < .01; ***p < .001. MPP = 1,3-Bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride; PHTPP = 4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol; NE = norepinephrine. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32233668), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-39681_rabbit-nnos-pab-310202416175279.jpg)
![Western Blot: MMR/CD206/Mannose Receptor Antibody (5C11) [H00004360-M02] - MRC1 monoclonal antibody (M02), clone 5C11. Analysis of MRC1 expression in human pancreas.](http://images.novusbio.com/fullsize/MMR-CD206-Mannose-Receptor-Antibody-5C11-Western-Blot-H00004360-M02-img0007.jpg "Western Blot: MMR/CD206/Mannose Receptor Antibody (5C11) [H00004360-M02] - MRC1 monoclonal antibody (M02), clone 5C11. Analysis of MRC1 expression in human pancreas.")
![Immunohistochemistry-Paraffin: MMR/CD206/Mannose Receptor Antibody (5C11) [H00004360-M02] - Analysis of monoclonal antibody to MRC1 on formalin-fixed paraffin-embedded human placenta. Antibody concentration 1.5 ug/ml.](http://images.novusbio.com/fullsize/MMR-CD206-Mannose-Receptor-Antibody-5C11-Immunohistochemistry-Paraffin-H00004360-M02-img0005.jpg)
![ELISA: MMR/CD206/Mannose Receptor Antibody (5C11) [H00004360-M02] - Detection limit for recombinant GST tagged MRC1 is approximately 0.03ng/ml as a capture antibody.](http://images.novusbio.com/fullsize/MMR-CD206-Mannose-Receptor-Antibody-5C11-ELISA-H00004360-M02-img0008.jpg)
![Immunohistochemistry: CCR2 Antibody [NBP1-48337] - Localization of CCR1 (binds to CCL8, CCL14, and CCL16), CCR2 (binds to CCL2, CCL8, and CCL16), CCR3 (binds to CCL11), and CXCR3 (binds to CXCL10) in the bovine endometrium and fetal trophoblast obtained from cows in their 18th day of pregnancy. Intensive immunoreactivity was observed in endometrial epithelial cells, glandular epithelial cells, or fetal trophoblast. No positive immunoreactivity was observed in the negative control (Control). Scale bar = 50 um. Image collected and cropped by CiteAb from the following publication (//www.mdpi.com/1422-0067/18/4/742), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunohistochemistry-NBP1-48337-img0017.jpg "Immunohistochemistry: CCR2 Antibody [NBP1-48337] - Localization of CCR1 (binds to CCL8, CCL14, and CCL16), CCR2 (binds to CCL2, CCL8, and CCL16), CCR3 (binds to CCL11), and CXCR3 (binds to CXCL10) in the bovine endometrium and fetal trophoblast obtained from cows in their 18th day of pregnancy. Intensive immunoreactivity was observed in endometrial epithelial cells, glandular epithelial cells, or fetal trophoblast. No positive immunoreactivity was observed in the negative control (Control). Scale bar = 50 um. Image collected and cropped by CiteAb from the following publication (//www.mdpi.com/1422-0067/18/4/742), licensed under a CC-BY license.")
![Western Blot: CCR2 Antibody [NBP1-48337] - Analysis of CCR2 in rat lysate. Image courtesy of product review submitted by Rasha Elbaz.](http://images.novusbio.com/fullsize/CCR2-Antibody-Western-Blot-NBP1-48337-img0005.jpg)
![Flow Cytometry: CCR2 Antibody - BSA Free [NBP1-48337] - An intracellular stain was performed on U2-OS cells with CCR2 NBP1-48337AF647 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/CCR2-Antibody---BSA-Free-Flow-Cytometry-NBP1-48337-img0020.jpg)
![Immunohistochemistry-Paraffin: CCR2 Antibody [NBP1-48337] - Analysis of FFPE tissue section of human liver cancer using 5 ug/ml concentration of CCR2 antibody. Intense cytoplasmic-membranous immune-staining was observed in the cancerous hepatocytes, whereas the staining was relatively weak in the cells adjacent to the fibrotic areas. [Magnification 40X]](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunohistochemistry-Paraffin-NBP1-48337-img0011.jpg)
![Immunohistochemistry-Paraffin: CCR2 Antibody [NBP1-48337] - Analysis of FFPE tissue section of human rectal adenocarcinoma using 5 ug/ml concentration of CCR2 antibody. The cancerous cells in the section developed a uniform but specific CCR2 immunopositivity whereas a weak staining was seen in the tumor stroma cells. [Magnification 40X]](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunohistochemistry-Paraffin-NBP1-48337-img0012.jpg)
![Immunohistochemistry-Paraffin: CCR2 Antibody [NBP1-48337] - Analysis of FFPE section of human esophageal squamous cell carcinoma (SCC) using 5 ug/ml concentration of CCR2 antibody. Strong cytoplasmic-membranous immune-staining was observed in SCC cells and a relatively weaker staining was seen in the tumor stroma cells. [Magnification 10X]](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunohistochemistry-Paraffin-NBP1-48337-img0013.jpg)
![Immunohistochemistry-Paraffin: CCR2 Antibody [NBP1-48337] - Analysis of FFPE tissue section of human normal kidney using 5 ug/ml concentration of CCR2 antibody. Strong cytoplasmic immunostaining was observed in the various renal cells (especially from tubules/ducts epithelium). The cells of Bowman's capsule depicted a very weak cytoplasmic staining for CCR2 protein. [Magnification 10X]](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunohistochemistry-Paraffin-NBP1-48337-img0014.jpg)
![Immunohistochemistry-Paraffin: CCR2 Antibody [NBP1-48337] - Analysis of FFPE tissue section of human normal breast using 5 ug/ml concentration of CCR2 antibody. The breast ductal/acinar epithelial cells showed a strong cytoplasmic-membranous CCR2 immune-positivity, whereas the intra-lobular connective tissue depicted weak staining. [Magnification 40X]](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunohistochemistry-Paraffin-NBP1-48337-img0015.jpg)
![Flow Cytometry: CCR2 Antibody [NBP1-48337] - An intracellular stain was performed on THP-1 cells with CCR Antibody NBP1-48337R (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 550.](http://images.novusbio.com/fullsize/CCR2-Antibody-Flow-Cytometry-NBP1-48337-img0016.jpg)
![Flow Cytometry: CCR2 Antibody [NBP1-48337] - An intracellular stain was performed on THP-1 cells with CCR2 Antibody NBP1-48337 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/CCR2-Antibody-Flow-Cytometry-NBP1-48337-img0018.jpg)
![Flow Cytometry: CCR2 Antibody - BSA Free [NBP1-48337] - An intracellular stain was performed on U2-OS cells with CCR2 NBP1-48337 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/CCR2-Antibody---BSA-Free-Flow-Cytometry-NBP1-48337-img0019.jpg)
![Western Blot: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Exosome or whole cell lysates (WCL) sample from MDA-MB-231 cells was loaded with 10 ug/lane. 10% SDS-PAGE. CD63 antibody (NBP2-32830) was used for primary antibody: 1:500, 4C, overnight. Image from verified customer review.](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Western-Blot-NBP2-32830-img0020.jpg "Western Blot: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Exosome or whole cell lysates (WCL) sample from MDA-MB-231 cells was loaded with 10 ug/lane. 10% SDS-PAGE. CD63 antibody (NBP2-32830) was used for primary antibody: 1:500, 4C, overnight. Image from verified customer review.")
![Immunocytochemistry/Immunofluorescence: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Immunofluorescence: - Azide and BSA Free [NBP2-34689] - IF staining of HeLa cells using AF488 labeled CD63 Monoclonal Antibody (MX-49. 129.5) (green). F-actin filaments are labeled with dylight 554 phalloidin (red) Nuclei stained with DAPI (blue).](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Immunocytochemistry-Immunofluorescence-NBP2-32830-img0011.jpg)
![Immunohistochemistry-Paraffin: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Formalin-fixed, paraffin-embedded Mouse spleen stained with CD63 Antibody (MX-49.129.5)](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Immunohistochemistry-Paraffin-NBP2-32830-img0014.jpg)
![Flow Cytometry: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Flow cytometric analysis of bead-bound exosomes derived from MCF-7 cells. CD63 Mouse Monoclonal antibody (MX-49.129.5) followed by goat anti-mouse IgG-CF568 (orange); unstained exosomes (gray).](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Flow-Cytometry-NBP2-32830-img0019.jpg)
![Western Blot: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Western Blot: CD63 Antibody (MX-49.129.5) - Azide and BSA Free [NBP2-34689] - Western blot of human spleen Lysate with CD63 Monoclonal Antibody (IMX-49. 129.5)](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Western-Blot-NBP2-32830-img0008.jpg)
![Immunohistochemistry-Paraffin: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Immunohistochemistry-Paraffin: CD63 Antibody (MX-49.129.5) - Azide and BSA Free [NBP2-34689] - Formalin-fixed, paraffin-embedded human prostate carcinoma stained with CD63 Monoclonal Antibody (MX-49. 129.5)](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Immunohistochemistry-Paraffin-NBP2-32830-img0009.jpg)
![Immunohistochemistry-Paraffin: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Formalin-fixed, paraffin-embedded human melanoma stained with CD63 Antibody (MX-49.129.5)](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Immunohistochemistry-Paraffin-NBP2-32830-img0013.jpg)
![Flow Cytometry: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Flow Cytometry: CD63 Antibody (MX-49.129.5) - Azide and BSA Free [NBP2-34689] - Flow Cytometry of NIH/3T3 Cells. Black: Cells alone; Green: Isotype Control; Red; PE-labeled CD63 Monoclonal Antibody (MX-49. 129.5)](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Flow-Cytometry-NBP2-32830-img0010.jpg)
![Flow Cytometry: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Flow Cytometric staining of CD63 on human PBMC cells. Black: cells alone; Green: Isotype Control; Red: PE-labeled CD63 Monoclonal Antibody (MX-49.129.5).](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Flow-Cytometry-NBP2-32830-img0015.jpg)
![Flow Cytometry: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Flow cytometry of MCF-7 cells unstained (gray) or stained with CF488A-labeled CD63 monoclonal antibody (MX-49.129.5) (green).](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Flow-Cytometry-NBP2-32830-img0016.jpg)
![Flow Cytometry: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Flow cytometry of bead-bound exosomes derived from MCF-7 cells. Unstained exosomes (gray) or stained with CF488A-labeled CD63 monoclonal antibody (MX-49.129.5) (green)](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Flow-Cytometry-NBP2-32830-img0017.jpg)
![Flow Cytometry: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Flow cytometric analysis of MCF-7 cells. CD63 Mouse Monoclonal antibody (MX-49.129.5) followed by goat anti-mouse IgG-CF568 (orange); unstained cells (gray).](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Flow-Cytometry-NBP2-32830-img0018.jpg)
![Flow Cytometry: CCR2 Antibody [NBP1-48338] - An intracellular stain was performed on THP-1 cells with CCR2 Antibody NBP1-48338G (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 488.](http://images.novusbio.com/fullsize/CCR2-Antibody-Flow-Cytometry-NBP1-48338-img0004.jpg "Flow Cytometry: CCR2 Antibody [NBP1-48338] - An intracellular stain was performed on THP-1 cells with CCR2 Antibody NBP1-48338G (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 488.")
![Immunocytochemistry/Immunofluorescence: CCR2 Antibody [NBP1-48338] - Analysis of CCR2 in NIH/3T3 cells.](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-48338-img0003.jpg)
![Immunohistochemistry: CCR2 Antibody [NBP1-48338] - Expression patterns of CCL2 and CCR2 in unwounded and wounded corneas of WT and MMP12 KO mice. Immunofluorescence of CCL2 chemokine receptor CCR2 in unwounded and chemically wounded (2-days after injury) WT and Mmp12-/- mouse corneas. Control images represent mouse corneas stained with secondary antibody only and without primary antibody. Nuclei were visualized by staining with DAPI (blue). Scale bars: 50 um. CCR2 staining was visualized in epithelial and stromal layers of unwounded and wounded WT and Mmp12-/- corneas. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-019-47831-z), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunohistochemistry-NBP1-48338-img0007.jpg)
![Flow Cytometry: CCR2 Antibody [NBP1-48338] - An intracellular stain was performed on THP-1 cells with CCR2 Antibody NBP1-48338F (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to FITC.](http://images.novusbio.com/fullsize/CCR2-Antibody-Flow-Cytometry-NBP1-48338-img0006.jpg)
![Flow Cytometry: CCR2 Antibody [NBP1-48338] - The Alexa Fluor 488 conjugate of this antibody was used: Mouse peripheral blood mononuclear cells were unstained (left) or stained (right) with CCR2 antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/CCR2-Antibody-Flow-Cytometry-NBP1-48338-img0005.jpg)
![Immunocytochemistry/ Immunofluorescence: CCR2 Antibody - BSA Free [NBP1-48338] - Expression patterns of CCL2 & CCR2 in unwounded & wounded corneas of WT & MMP12 KO mice. (A) Immunofluorescence of CCL2 chemokine & (B) its receptor CCR2 in unwounded & chemically wounded (2-days after injury) WT & Mmp12−/− mouse corneas. Control images represent mouse corneas stained with secondary antibody only & without primary antibody. Nuclei were visualized by staining with DAPI (blue). Scale bars: 50 µm. A magnified image of a wounded WT cornea shows perinuclear expression of CCL2 (orange box). CCL2 staining was visualized in epithelial, stromal, & endothelial layers of wounded WT & Mmp12−/− corneas. CCR2 staining was visualized in epithelial & stromal layers of unwounded & wounded WT & Mmp12−/− corneas. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31399604), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-48338_rabbit-polyclonal-ccr2-antibody-310202415175260.jpg)
![Western Blot: ATR Antibody (2B5) [NB100-308] - Human Raji whole cell extract. The HRP-conjugated anti-mouse IgG antibody (NBP2-19382) was used to detect the primary antibody.](http://images.novusbio.com/fullsize/ATR-Antibody-2B5-Western-Blot-NB100-308-img0007.jpg "Western Blot: ATR Antibody (2B5) [NB100-308] - Human Raji whole cell extract. The HRP-conjugated anti-mouse IgG antibody (NBP2-19382) was used to detect the primary antibody.")
![Western Blot: ATR Antibody (2B5) [NB100-308] - Non-transfected (-) and transfected (+) 293T whole cell extracts (30 ug) were separated by 5% SDS-PAGE, and the membrane was blotted with ATR antibody [2B5] diluted at 1:500.](http://images.novusbio.com/fullsize/ATR-Antibody-2B5-Western-Blot-NB100-308-img0004.jpg)
![<b>Orthogonal Strategies Validation. </b>Western Blot: ATR Antibody (2B5) [NB100-308] - Raji whole cell and nuclear extracts (30 ug) were separated by 5% SDS-PAGE, and the membrane was blotted with ATR antibody diluted at 1:500.](http://images.novusbio.com/fullsize/ATR-Antibody-2B5-Western-Blot-NB100-308-img0005.jpg)
![Flow Cytometry: CD4 Antibody (RPA-T4) [NBP2-25199] - Analysis using the Alexa Fluor (R) 700 conjugate of NBP2-27216. Staining of human PBMC. Image from verified customer review.](http://images.novusbio.com/fullsize/CD4-Antibody-RPA-T4-Flow-Cytometry-NBP2-25199-img0007.jpg "Flow Cytometry: CD4 Antibody (RPA-T4) [NBP2-25199] - Analysis using the Alexa Fluor (R) 700 conjugate of NBP2-27216. Staining of human PBMC. Image from verified customer review.")
![Flow Cytometry: CD4 Antibody (RPA-T4) [NBP2-25199] - Analysis using the PE conjugate of NBP2-27216. Staining of CD4 in human PBMC using anti-CD4 antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/CD4-Antibody-RPA-T4-Flow-Cytometry-NBP2-25199-img0004.jpg)
![Flow Cytometry: CD4 Antibody (RPA-T4) [NBP2-25199] - Analysis using the FITC conjugate of NBP2-27216. Staining of CD4 in 1x10^6 human PBMC using 10 ul (0.1 ug) of was used to test this product. Propidium iodide negative lymphocyte population gated for analysis. Image using the Azide Free format of this antibody.](http://images.novusbio.com/fullsize/CD4-Antibody-RPA-T4-Flow-Cytometry-NBP2-25199-img0011.jpg)
![Flow Cytometry: CD4 Antibody (RPA-T4) [NBP2-25199] - Analysis using the DyLight 405 conjugate of NBP2-27216. Staining of CD4 in human PBMCs using anti-CD4 antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/CD4-Antibody-RPA-T4-Flow-Cytometry-NBP2-25199-img0005.jpg)
![Flow Cytometry: CD4 Antibody (RPA-T4) [NBP2-25199] - Analysis using the PE conjugate of NBP2-27216. Staining of CD4 in 1x10^6 human PBMC using 10 ul (0.1 ug) of this antibody. Green represents isotype control; red represents anti-CD4 antibody. Image using the Azide Free format of this antibody.](http://images.novusbio.com/fullsize/CD4-Antibody-RPA-T4-Flow-Cytometry-NBP2-25199-img0009.jpg)
![Flow Cytometry: CD4 Antibody (RPA-T4) [NBP2-25199] - Analysis using the Allophycocyanin conjugate of NBP2-27216. Staining of CD4 in 1x10^6 human PBMC using 10 ul (0.1 ug) of was used to test this product. Propidium iodide negative lymphocyte population gated for analysis. Image using the Azide Free format of this antibody.](http://images.novusbio.com/fullsize/CD4-Antibody-RPA-T4-Flow-Cytometry-NBP2-25199-img0010.jpg)
![Flow Cytometry: CD4 Antibody (RPA-T4) - Azide and BSA Free [NBP2-25199] - analysis of CD4 in human PBMCs using 0.1 ug of this antibody. Secondary antibody is goat anti-mouse PE.](http://images.novusbio.com/fullsize/nbp2-25199_mouse-monoclonal-cd4-antibody-rpa-t4-imgenex-img-5916a-25ug-17720241044654.jpg)
![Immunocytochemistry/Immunofluorescence: nNOS Antibody [NB100-858] - Action potentials were evoked with depolarizing current pulses. (A) Neuron from colonic specimen of non-treated patient fired 1 action potential in response to a depolarizing current. (A') Intracellular injection of carboxyfluorescein during recording confirmed Dogiel type I, uniaxonal morphology. (A](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunocytochemistry-Immunofluorescence-NB100-858-img0005.jpg "Immunocytochemistry/Immunofluorescence: nNOS Antibody [NB100-858] - Action potentials were evoked with depolarizing current pulses. (A) Neuron from colonic specimen of non-treated patient fired 1 action potential in response to a depolarizing current. (A') Intracellular injection of carboxyfluorescein during recording confirmed Dogiel type I, uniaxonal morphology. (A")
![Immunohistochemistry-Paraffin: nNOS Antibody [NB100-858] - Staining of paraffin embedded Human Cortex. Steamed antigen retrieval with citrate buffer pH 6, AP-staining. Antibody at 2.5 ug/mL.](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunohistochemistry-Paraffin-NB100-858-img0006.jpg)
![Flow Cytometry: nNOS Antibody [NB100-858] - Flow cytometric analysis of paraformaldehyde fixed Kelly cells (blue line), permeabilized with 0.5% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (1 ug/mL). IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.](http://images.novusbio.com/fullsize/nNOS-Antibody-Flow-Cytometry-NB100-858-img0003.jpg)
![Immunocytochemistry/Immunofluorescence: nNOS Antibody [NB100-858] - Immunofluorescence analysis of paraformaldehyde fixed HeLa cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL), showing membrane, cytoplasmic and nuclear staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL).](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunocytochemistry-Immunofluorescence-NB100-858-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: nNOS Antibody [NB100-858] - Wholemount preparations of the myenteric neurons in the distal colon segments following 3 (2a-2d) and 7 (4a-4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 3 (1a-1d) and 7 (3a-3d) days. Myenteric ganglia and neurons labeled with beta-Tubulin Tuj1 (red), nuclei labeled with DAPI (blue) (arrows) can be seen within the ganglion (1b). Smooth muscle cells (asterisks) are also labeled with DAPI (1b). Significant increase in the proportion of nNOS neurons (green) can be seen at both Days 3 and 7 after oxaliplatin treatment. Scale bar = 20 um. Image collected and cropped by CiteAb from the following publication (www.journal.frontiersin.org/article/10.3389/fnins.2013.00030/abstract) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunocytochemistry-Immunofluorescence-NB100-858-img0004.jpg)
![Immunocytochemistry/ Immunofluorescence: nNOS Antibody [NB100-858] - (A) Wholemount preparations of the myenteric neurons in the distal colon segments following 3 (2a–2d) & 7 (4a–4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 3 (1a–1d) & 7 (3a–3d) days. Myenteric ganglia & neurons labeled with beta -Tubulin Tuj1 (red), nuclei labeled with DAPI (blue) (arrows) can be seen within the ganglion (1b). Smooth muscle cells (asterisks) are also labeled with DAPI (1b). Significant increase in the proportion of NOS neurons (green) can be seen at both Days 3 & 7 after oxaliplatin treatment. Scale bar = 20 μm. (B) Wholemount preparations of the myenteric neurons in the distal colon segments following 14 (2a–2d) & 21 (4a–4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 14 (1a–1d) & 21 (3a–3d) days. The reduction in total number of neurons & increase in the proportion of NOS neurons was found at both Days 14 & 21 after oxaliplatin treatment. Scale bar = 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23486839), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-858_goat-polyclonal-nnos-antibody-310202416284925.jpg)
![Immunocytochemistry/ Immunofluorescence: nNOS Antibody [NB100-858] - (A) Wholemount preparations of the myenteric neurons in the distal colon segments following 3 (2a–2d) & 7 (4a–4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 3 (1a–1d) & 7 (3a–3d) days. Myenteric ganglia & neurons labeled with beta -Tubulin Tuj1 (red), nuclei labeled with DAPI (blue) (arrows) can be seen within the ganglion (1b). Smooth muscle cells (asterisks) are also labeled with DAPI (1b). Significant increase in the proportion of NOS neurons (green) can be seen at both Days 3 & 7 after oxaliplatin treatment. Scale bar = 20 μm. (B) Wholemount preparations of the myenteric neurons in the distal colon segments following 14 (2a–2d) & 21 (4a–4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 14 (1a–1d) & 21 (3a–3d) days. The reduction in total number of neurons & increase in the proportion of NOS neurons was found at both Days 14 & 21 after oxaliplatin treatment. Scale bar = 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23486839), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-858_goat-polyclonal-nnos-antibody-310202416284920.jpg)